MTTI Reports on 225Ac-EBTATE and 177Lu-EBTATE Radiopharmaceuticals at 2024 Society of Nuclear Medicine and Molecular Imaging Annual Meeting
2024年5月21日 - 7:01PM
ビジネスワイヤ(英語)
Molecular Targeting Technologies, Inc. (MTTI), will update
findings on both 177Lu-EBTATE clinical and 225Ac-EBTATE preclinical
work during the 2024 SNMMI meeting in Toronto June 8-11 (exhibition
booth #1819).
177Lu-EBTATE® an EvaThera drug, is the first patented
long-acting peptide targeted radiotherapeutic drugs. It selectively
targets and binds to somatostatin receptor 2 on neuroendocrine and
other tumors, which are then killed by the radionuclide payload.
Evans blue in EBTATE binds to serum albumin, extending in vivo
circulatory half-life and tumor residence time, enabling effective
use of significantly lower radiopharmaceutical activity and fewer
dosing cycles vs. the current standard of care (SOC). These
benefits are also evident in recent studies of the 225Ac-EBTATE
homolog.
Professor Zhaohui Zhu, MD, Peking Union Medical College
Hospital, reflected “In our 3-year follow up on 30 patients* with
metastatic neuroendocrine tumors (mNETs), 177Lu-EBTATE demonstrated
good safety, with no nephro- or hepatoxicity and 86% disease
control rate using 60% less radioactivity than 177Lu-DOTATATE. We
observed low incidence of grade 3 hematoxicity (3.4% vs 15% of
reported SOC) and no long-term nephrotoxicity of any grade.”
The study “Long acting 225Ac-EBTATE is highly efficacious
against somatostatin receptor-2-positive small-cell lung cancer
(SCLC)**” has been accepted for presentation at 2024 SNMMI.
Professor Humphrey Fonge of the University of Saskatchewan
commented, "225Ac-EBTATE (2x 30 kBq administered 10 days apart) was
effective against SCLC with 80% complete remissions and 100%
survival. Treatment yielded a 2-fold greater tumor growth
inhibition when compared with 225Ac-DOTATATE, at 60% less
administered radioactivity. Toxicity, as measured by body weight,
blood counts, and chemistry showed that 225Ac-EBTATE was well
tolerated at a highly effective dose. 225Ac-EBTATE shows great
promise against SCLC."
Chris Pak, President & CEO of MTTI commented: “We are
pleased to learn that 177Lu-EBTATE exhibited no safety concerns and
was effective at a lower dose than SOC in mNET patients. We are
also encouraged that 225Ac-EBTATE out-performed 225Ac-DOTATATE,
providing a 2-fold greater tumor growth inhibition in preclinical
findings using a much lower dose of radioactivity. We look forward
to advancing our clinical trials with these radiotherapeutic drugs
in small-cell lung and other cancers.”
Molecular Targeting Technologies, Inc. (MTTI). MTTI is a
private, clinical stage biotech developing targeted
radiotherapeutics for rare cancers. MTTI is committed to building
value by translating innovative radiopharmaceuticals to improve
human health. For more information: www.mtarget.com.
*Safety and efficacy of peptide receptor radionuclide therapy
with 177Lu-DOTA-EB-TATE in patients with metastatic neuroendocrine
tumors. Theranostics 2022; 12: 6437-6445
**The data will be presented in 2024 SNMMI. Fabrice Njotu,
Humphrey Fonge et al. of the University of Saskatchewan, and
Molecular Targeting Technologies, Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240521449624/en/
Chris Pak, Email: cpak@mtarget.com